메뉴 건너뛰기




Volumn 76, Issue 1, 2009, Pages 37-44

JUPITER to earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

EID: 60849135440     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75a.08105     Document Type: Article
Times cited : (8)

References (70)
  • 1
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 2
    • 1842765431 scopus 로고    scopus 로고
    • Intensive statin therapy - a sea change in cardiovascular prevention
    • Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004; 350:1562-1564.
    • (2004) N Engl J Med , vol.350 , pp. 1562-1564
    • Topol, E.J.1
  • 3
    • 21444455072 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in coronary disease
    • Cannon CP, Murphy SA, Braunwald E. Intensive lipid lowering with atorvastatin in coronary disease. N Engl J Med 2005; 353:93-96.
    • (2005) N Engl J Med , vol.353 , pp. 93-96
    • Cannon, C.P.1    Murphy, S.A.2    Braunwald, E.3
  • 4
    • 33748283766 scopus 로고    scopus 로고
    • Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
    • Cohen DJ, Carrozza JP, Baim DS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341:1853-1854.
    • (1999) N Engl J Med , vol.341 , pp. 1853-1854
    • Cohen, D.J.1    Carrozza, J.P.2    Baim, D.S.3
  • 5
    • 33645524176 scopus 로고    scopus 로고
    • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial
    • Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
    • (2006) JAMA , vol.295 , pp. 1556-1565
    • Nissen, S.E.1    Nicholls, S.J.2    Sipahi, I.3
  • 6
    • 10744225301 scopus 로고    scopus 로고
    • Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080.
    • (2004) JAMA , vol.291 , pp. 1071-1080
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 7
    • 27644544308 scopus 로고    scopus 로고
    • Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis
    • Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1855-1862
    • Robinson, J.G.1    Smith, B.2    Maheshwari, N.3    Schrott, H.4
  • 8
    • 0035895319 scopus 로고    scopus 로고
    • An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
    • Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103:276-283.
    • (2001) Circulation , vol.103 , pp. 276-283
    • Aikawa, M.1    Rabkin, E.2    Sugiyama, S.3
  • 9
    • 23944445364 scopus 로고    scopus 로고
    • Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol
    • Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96:24F-33F.
    • (2005) Am J Cardiol , vol.96
    • Liao, J.K.1
  • 10
    • 19944429519 scopus 로고    scopus 로고
    • Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
    • (2005) N Engl J Med , vol.352 , pp. 29-38
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 11
    • 11344279659 scopus 로고    scopus 로고
    • C-reactive protein levels and outcomes after statin therapy
    • Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
    • (2005) N Engl J Med , vol.352 , pp. 20-28
    • Ridker, P.M.1    Cannon, C.P.2    Morrow, D.3
  • 12
    • 0037414194 scopus 로고    scopus 로고
    • Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy
    • Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289:1675-1680.
    • (2003) JAMA , vol.289 , pp. 1675-1680
    • Shishehbor, M.H.1    Aviles, R.J.2    Brennan, M.L.3
  • 13
    • 0043166521 scopus 로고    scopus 로고
    • Statins promote potent systemic antioxidant effects through specific inflammatory pathways
    • Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-431.
    • (2003) Circulation , vol.108 , pp. 426-431
    • Shishehbor, M.H.1    Brennan, M.L.2    Aviles, R.J.3
  • 14
    • 0035572718 scopus 로고    scopus 로고
    • Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
    • Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
    • (2001) Arterioscler Thromb Vasc Biol , vol.21 , pp. 1712-1719
    • Takemoto, M.1    Liao, J.K.2
  • 15
    • 33747313198 scopus 로고    scopus 로고
    • Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    • Shishehbor MH, Patel T, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med 2006; 73:760-766.
    • (2006) Cleve Clin J Med , vol.73 , pp. 760-766
    • Shishehbor, M.H.1    Patel, T.2    Bhatt, D.L.3
  • 16
    • 0035963529 scopus 로고    scopus 로고
    • Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    • Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-1965.
    • (2001) N Engl J Med , vol.344 , pp. 1959-1965
    • Ridker, P.M.1    Rifai, N.2    Clearfield, M.3
  • 17
    • 0032566401 scopus 로고    scopus 로고
    • Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
    • Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-733.
    • (1998) Circulation , vol.98 , pp. 731-733
    • Ridker, P.M.1    Buring, J.E.2    Shih, J.3    Matias, M.4    Hennekens, C.H.5
  • 18
    • 0034704893 scopus 로고    scopus 로고
    • C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
    • Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
    • (2000) N Engl J Med , vol.342 , pp. 836-843
    • Ridker, P.M.1    Hennekens, C.H.2    Buring, J.E.3    Rifai, N.4
  • 19
    • 85136357712 scopus 로고    scopus 로고
    • Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
    • Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
  • 20
    • 0035103498 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease
    • Rifai N, Ridkar PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403-411.
    • (2001) Clin Chem , vol.47 , pp. 403-411
    • Rifai, N.1    Ridkar, P.M.2
  • 21
    • 0041589763 scopus 로고    scopus 로고
    • Using C-reactive protein to assess cardiovascular disease risk
    • Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med 2003; 70:634-640.
    • (2003) Cleve Clin J Med , vol.70 , pp. 634-640
    • Shishehbor, M.H.1    Bhatt, D.L.2    Topol, E.J.3
  • 22
    • 0030956673 scopus 로고    scopus 로고
    • Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
    • Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
    • (1997) N Engl J Med , vol.336 , pp. 973-979
    • Ridker, P.M.1    Cushman, M.2    Stampfer, M.J.3    Tracy, R.P.4    Hennekens, C.H.5
  • 24
    • 0034218523 scopus 로고    scopus 로고
    • Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation
    • Ridker PM. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. Curr Cardiol Rep 2000; 2:269-273.
    • (2000) Curr Cardiol Rep , vol.2 , pp. 269-273
    • Ridker, P.M.1
  • 25
    • 0037469255 scopus 로고    scopus 로고
    • C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women
    • Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
    • (2003) Circulation , vol.107 , pp. 391-397
    • Ridker, P.M.1    Buring, J.E.2    Cook, N.R.3    Rifai, N.4
  • 26
    • 0037469232 scopus 로고    scopus 로고
    • Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
    • Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
    • (2003) Circulation , vol.107 , pp. 499-511
    • Pearson, T.A.1    Mensah, G.A.2    Alexander, R.W.3
  • 27
    • 0035897696 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
    • Executive Summary of the Third Report of the National Cholesterol Education Program NCEP
    • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 28
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 29
    • 0036156342 scopus 로고    scopus 로고
    • The MRC/BHF Heart Protection Study: Preliminary results
    • Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56:53-56.
    • (2002) Int J Clin Pract , vol.56 , pp. 53-56
    • Collins, R.1    Peto, R.2    Armitage, J.3
  • 30
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 31
    • 4544243333 scopus 로고    scopus 로고
    • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
    • de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307-1316.
    • (2004) JAMA , vol.292 , pp. 1307-1316
    • de Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3
  • 32
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 33
    • 0036899472 scopus 로고    scopus 로고
    • Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial
    • Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002; 23:1931-1937.
    • (2002) Eur Heart J , vol.23 , pp. 1931-1937
    • Liem, A.H.1    van Boven, A.J.2    Veeger, N.J.3
  • 34
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 35
    • 0033536298 scopus 로고    scopus 로고
    • Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
    • Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341:70-76.
    • (1999) N Engl J Med , vol.341 , pp. 70-76
    • Pitt, B.1    Waters, D.2    Brown, W.V.3
  • 36
    • 26844447541 scopus 로고    scopus 로고
    • Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE IT-TIMI 22 trial
    • Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46:1405-1410.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1405-1410
    • Ray, K.K.1    Cannon, C.P.2    McCabe, C.H.3
  • 37
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial
    • Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711-1718.
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 38
    • 0037178569 scopus 로고    scopus 로고
    • Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
    • Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:321 5-3222.
    • (2002) JAMA , vol.287 , Issue.321 , pp. 5-3222
    • Serruys, P.W.1    de Feyter, P.2    Macaya, C.3
  • 39
    • 33947303030 scopus 로고    scopus 로고
    • A review of high-dose statin therapy: Targeting cholesterol and inflammation in atherosclerosis
    • Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28:664-672.
    • (2007) Eur Heart J , vol.28 , pp. 664-672
    • Patel, T.N.1    Shishehbor, M.H.2    Bhatt, D.L.3
  • 40
    • 0033630648 scopus 로고    scopus 로고
    • Novel risk factors and markers for coronary disease
    • Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45:391-418.
    • (2000) Adv Intern Med , vol.45 , pp. 391-418
    • Ridker, P.M.1
  • 41
    • 0035799331 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
    • Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818.
    • (2001) Circulation , vol.103 , pp. 1813-1818
    • Ridker, P.M.1
  • 42
    • 0032568486 scopus 로고    scopus 로고
    • C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
    • Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-2011.
    • (1998) Circulation , vol.97 , pp. 2007-2011
    • Ridker, P.M.1    Glynn, R.J.2    Hennekens, C.H.3
  • 43
    • 21844451117 scopus 로고    scopus 로고
    • C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study
    • Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112:25-31.
    • (2005) Circulation , vol.112 , pp. 25-31
    • Cushman, M.1    Arnold, A.M.2    Psaty, B.M.3
  • 44
    • 34248641015 scopus 로고    scopus 로고
    • C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus
    • Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49:2129-2138.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 2129-2138
    • Ridker, P.M.1
  • 45
    • 0035806626 scopus 로고    scopus 로고
    • Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study
    • Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
    • (2001) JAMA , vol.286 , pp. 64-70
    • Albert, M.A.1    Danielson, E.2    Rifai, N.3    Ridker, P.M.4
  • 46
    • 0033587667 scopus 로고    scopus 로고
    • Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
    • Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235.
    • (1999) Circulation , vol.100 , pp. 230-235
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.A.3    Sacks, F.4    Braunwald, E.5
  • 47
    • 20244363246 scopus 로고    scopus 로고
    • Activation of inflammation and coagulation after infusion of C-reactive protein in humans
    • Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714-716.
    • (2005) Circ Res , vol.96 , pp. 714-716
    • Bisoendial, R.J.1    Kastelein, J.J.2    Levels, J.H.3
  • 48
    • 23844479596 scopus 로고    scopus 로고
    • Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice
    • Schwedler SB, Amann K, Wernicke K, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112:1016-1023.
    • (2005) Circulation , vol.112 , pp. 1016-1023
    • Schwedler, S.B.1    Amann, K.2    Wernicke, K.3
  • 49
    • 49449085233 scopus 로고    scopus 로고
    • Multiple biomarkers and cardiovascular risk
    • Pfister R. Hellmich M. Multiple biomarkers and cardiovascular risk. N Engl J Med 2008; 359:760.
    • (2008) N Engl J Med , vol.359 , pp. 760
    • Pfister, R.1    Hellmich, M.2
  • 50
    • 55249105922 scopus 로고    scopus 로고
    • Elevated C-reactive protein in atherosclerosis - chicken or egg?
    • Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis - chicken or egg? N Engl J Med 2008; 359:1953-1955.
    • (2008) N Engl J Med , vol.359 , pp. 1953-1955
    • Schunkert, H.1    Samani, N.J.2
  • 51
    • 1842587885 scopus 로고    scopus 로고
    • C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
    • Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:13;87-1397.
    • (2004) N Engl J Med , vol.350 , Issue.13 , pp. 87-1397
    • Danesh, J.1    Wheeler, J.G.2    Hirschfield, G.M.3
  • 52
    • 0037156465 scopus 로고    scopus 로고
    • Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk?
    • Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 2002; 162:867-869.
    • (2002) Arch Intern Med , vol.162 , pp. 867-869
    • Kushner, I.1    Sehgal, A.R.2
  • 53
    • 56749106309 scopus 로고    scopus 로고
    • Expanding the orbit of primary prevention - moving beyond JUPITER
    • Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med 2008; 359:2280-2282.
    • (2008) N Engl J Med , vol.359 , pp. 2280-2282
    • Hlatky, M.A.1
  • 54
    • 3142624781 scopus 로고    scopus 로고
    • Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome
    • Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep 2004; 6:243-250:
    • (2004) Curr Atheroscler Rep , vol.6 , pp. 243-250
    • Shishehbor, M.H.1    Hazen, S.L.2
  • 56
    • 40949127806 scopus 로고    scopus 로고
    • Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk
    • Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265-1276.
    • (2008) JAMA , vol.299 , pp. 1265-1276
    • Bhattacharyya, T.1    Nicholls, S.J.2    Topol, E.J.3
  • 57
    • 45449120489 scopus 로고    scopus 로고
    • Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: Volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study
    • Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52:24-32.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 24-32
    • Choi, S.H.1    Chae, A.2    Miller, E.3
  • 58
    • 18244403498 scopus 로고    scopus 로고
    • Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial
    • Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial JAMA 2005; 293:2245-2256.
    • (2005) JAMA , vol.293 , pp. 2245-2256
    • Hakonarson, H.1    Thorvaldsson, S.2    Helgadottir, A.3
  • 59
    • 43049116177 scopus 로고    scopus 로고
    • The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans
    • Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653-1662.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1653-1662
    • Ky, B.1    Burke, A.2    Tsimikas, S.3
  • 60
    • 33847671755 scopus 로고    scopus 로고
    • Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque
    • Levy AR, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007; 27:134-140.
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 134-140
    • Levy, A.R.1    Levy, J.E.2    Kalet-Litman, S.3
  • 61
    • 1542436231 scopus 로고    scopus 로고
    • Pharmacogenomics in cardiovascular diseases
    • Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular diseases. Curr Probl Cardiol 2003; 28:317-347
    • (2003) Curr Probl Cardiol , vol.28 , pp. 317-347
    • Mukherjee, D.1    Topol, E.J.2
  • 62
    • 0030590742 scopus 로고    scopus 로고
    • West of Scotland Coronary prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-1342.
    • West of Scotland Coronary prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-1342.
  • 63
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 64
    • 34247267133 scopus 로고    scopus 로고
    • Safety of aggressive lipid management
    • Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49:1753-1762.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1753-1762
    • Davidson, M.H.1    Robinson, J.G.2
  • 65
    • 8844243968 scopus 로고    scopus 로고
    • Rosuvastatin safety: Lessons from the FDA review and post-approval surveillance
    • Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004; 3:547-557.
    • (2004) Expert Opin Drug Saf , vol.3 , pp. 547-557
    • Davidson, M.H.1
  • 66
  • 67
    • 0035825928 scopus 로고    scopus 로고
    • Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
    • McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87:28B-32B.
    • (2001) Am J Cardiol , vol.87
    • McTaggart, F.1    Buckett, L.2    Davidson, R.3
  • 68
    • 33645870418 scopus 로고    scopus 로고
    • Statin safety: Lessons from new drug applications for marketed statins
    • Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97:44C-51C.
    • (2006) Am J Cardiol , vol.97
    • Jacobson, T.A.1
  • 69
    • 7044237064 scopus 로고    scopus 로고
    • Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
    • Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94:1140-1146.
    • (2004) Am J Cardiol , vol.94 , pp. 1140-1146
    • Jacobson, T.A.1
  • 70
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.